methyl N-[3-(dimethylamino)propyl]-N-methylcarbamate | 1595712-12-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methyl N-[3-(dimethylamino)propyl]-N-methylcarbamate
• CAS: 1595712-12-1
• 化学式: C₈H₁₈N₂O₂
• 分子量: 174.24
• InChiKey: QRUYCLFAYXRXME-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  32.8
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] MTORC MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS DE MTORC ET LEURS UTILISATIONS
  申请人：AEOVIAN PHARMACEUTICALS INC

  公开号：WO2020154447A1

  公开（公告）日：2020-07-30

  Novel rapamycin analogs and uses thereof are disclosed herein. The rapamycin analogs of the present disclosure show increased mTORC1 specificity and lowered mTORC2 specificity relative to rapamycin.

  本文披露了新型雷帕霉素类似物及其用途。本公开的雷帕霉素类似物相对于雷帕霉素表现出增加的mTORC1特异性和降低的mTORC2特异性。
• COMPOSITIONS AND METHODS FOR DELIVERING MESSENGER RNA
  申请人：Arbutus Biopharma Corporation

  公开号：EP3677567A1

  公开（公告）日：2020-07-08

  The present invention provides compositions comprising mRNA molecules encapsulated within lipid particles. The lipid particles comprise a cationic lipid, a non-cationic lipid, and an mRNA molecule that is encapsulated within the lipid particle. The compositions are useful, for example, to introduce the mRNA molecules into a human subject where they are translated to produce a polypeptide that functions to ameliorate one or more symptoms of a disease. The invention also provides cationic lipids that are useful for preparing the compositions of the invention.

  本发明提供了包含封装在脂质颗粒内的 mRNA 分子的组合物。脂质颗粒包括阳离子脂质、非阳离子脂质和封装在脂质颗粒内的 mRNA 分子。这些组合物可用于将 mRNA 分子导入人体，在人体中翻译产生多肽，从而改善疾病的一种或多种症状。本发明还提供了可用于制备本发明组合物的阳离子脂质。
• mTORC modulators and uses thereof
  申请人：Aeovian Pharmaceuticals, Inc.

  公开号：US11021492B2

  公开（公告）日：2021-06-01

  Novel rapamycin analogs and uses thereof are disclosed herein. The rapamycin analogs of the present disclosure show increased mTORC1 specificity and lowered mTORC2 specificity relative to rapamycin.

  本文公开了新型雷帕霉素类似物及其用途。 与雷帕霉素相比，本公开的雷帕霉素类似物显示出更高的 mTORC1 特异性和更低的 mTORC2 特异性。
• MTORC MODULATORS AND USES THEREOF
  申请人：Aeovian Pharmaceuticals, Inc.

  公开号：US20210002300A1

  公开（公告）日：2021-01-07

  Novel rapamycin analogs and uses thereof are disclosed herein. The rapamycin analogs of the present disclosure show increased mTORC1 specificity and lowered mTORC2 specificity relative to rapamycin.
• [EN] MTORC1 MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS DE MTORC1 ET LEURS UTILISATIONS
  申请人：AEOVIAN PHARMACEUTICALS INC

  公开号：WO2021195599A1

  公开（公告）日：2021-09-30

  The disclosure provides compounds and salts that show high selectivity and inhibitory activity for mTORC1 and uses thereof for the treatment of disease.